UPDATE 1-U.S. judge accepts Abbott misbranding settlement
WASHINGTON Oct 2 (Reuters) - Abbott Laboratories Inc must pay $700 million in fines and other costs for illegal marketing of its drug Depakote, in line with a p reviously announced settlement, the U.S. Justice Department said on Tuesday.
The pharmaceutical maker said in May it would plead guilty to a misdemeanor violation of misbranding and pay $1.6 billion to state and federal authorities.
Abbott marketed Depakote for conditions including depression, anxiety and drug withdrawal while the drug did not have government approval for those uses, prosecutors said.
A federal judge in Virginia sentenced Abbott at a hearing on Tuesday as part of the broader settlement, the Justice department said.
The settlement includes a $500 million criminal fine, $198.5 million in lost profits and a $1.5 million payment to Virginia state officials. Abbott will be on probation for five years.
That is in addition to an $800 million civil settlement with federal and state officials and $100 million to U.S. states to resolve consumer protection matters.
An Abbott spokesman said the company was pleased to resolve the matter.
- Colorado baker discriminated by denying gay couple wedding cake: judge
- Amish girl in Ohio will not be forced to resume chemo for cancer
- Flights delayed as air pollution hits record in Shanghai
- WTO overcomes last minute hitch to reach its first global trade deal
- French launch Central African Republic mission but deaths mount